Expert Perspectives on the Evolving Treatment Landscape of Multiple Myeloma
EP. 1: Data Updates in the Frontline Treatment of Patients With Transplant-Eligible Multiple Myeloma
BySagar Lonial, MD,Amrita Krishnan, MD,Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center,Hana Safah, MD,Noopur S. Raje, MD Sagar Lonial, MD, introduces the expert panel and starts a conversation on data updates in the treatment of transplant-eligible multiple myeloma.
EP. 2: Considerations for Frontline Treatment in Transplant-Ineligible Multiple Myeloma
BySagar Lonial, MD,Amrita Krishnan, MD,Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center,Hana Safah, MD,Noopur S. Raje, MD Hana Safah, MD, explains the common treatment approaches for patients with transplant-ineligible multiple myeloma.
EP. 3: Defining Frailty in Multiple Myeloma for Optimal Treatment
BySagar Lonial, MD,Amrita Krishnan, MD,Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center,Hana Safah, MD,Noopur S. Raje, MD Amrita Krishnan, MD, and Hana Safah, MD, discuss how to measure frailty in patient with multiple myeloma.
EP. 4: Approaches to Treatment Duration in Newly-Diagnosed Multiple Myeloma
BySagar Lonial, MD,Amrita Krishnan, MD,Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center,Hana Safah, MD,Noopur S. Raje, MD Noopur Raje, MD, details the data on treatment duration in older patients with multiple myeloma and transplant-eligible patients.
EP. 5: Relapse in Multiple Myeloma: Biochemical and Chemical
BySagar Lonial, MD,Amrita Krishnan, MD,Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center,Hana Safah, MD,Noopur S. Raje, MD Dr Amrita Krishnan explains the difference between biochemical and clinical relapse in multiple myeloma.
EP. 6: Data Updates in the Treatment of Relapsed Multiple Myeloma
BySagar Lonial, MD,Amrita Krishnan, MD,Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center,Hana Safah, MD,Noopur S. Raje, MD Drs Hana Safah and Krina Patel share data from key clinical trials investigating the treatment of relapsed multiple myeloma.
EP. 7: Strategies for Treatment of Multiple Myeloma at Late Relapse
BySagar Lonial, MD,Amrita Krishnan, MD,Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center,Hana Safah, MD,Noopur S. Raje, MD The panel debates the options for treatment of late relapsed multiple myeloma.
EP. 8: Quadruplet Combination Therapies in Relapsed Multiple Myeloma
BySagar Lonial, MD,Amrita Krishnan, MD,Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center,Hana Safah, MD,Noopur S. Raje, MD Hana Safa, MD, shares data on quadruplet therapies in the treatment of relapsed multiple myeloma.
EP. 9: Considerations for Treatment Decision-Making in Early-Relapse Multiple Myeloma
BySagar Lonial, MD,Amrita Krishnan, MD,Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center,Hana Safah, MD,Noopur S. Raje, MD Noopur Raje, MD, explains the treatment decision-making process for early relapse multiple myeloma.
EP. 10: CD38 Monoclonal Antibodies for Early Relapsed Multiple Myeloma and the Risk of COVID Infection
BySagar Lonial, MD,Amrita Krishnan, MD,Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center,Hana Safah, MD,Noopur S. Raje, MD The panel discusses the strategies for reducing or preventing COVID infection in patients being treated for early relapse multiple myeloma with CD38 monoclonal antibodies.
EP. 11: BCMA-Targeting Bispecifics in Relapsed/Refractory Multiple Myeloma
BySagar Lonial, MD,Amrita Krishnan, MD,Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center,Hana Safah, MD,Noopur S. Raje, MD Hana Safah, MD, and Noopur Raje, MD, discuss data on BCMA-targeting bispecifics teclistamab and elrantamab for treatment of relapsed/refractory multiple myeloma.
EP. 12: Retreatment with a BCMA-Targeting Bispecific for R/R MM
BySagar Lonial, MD,Amrita Krishnan, MD,Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center,Hana Safah, MD,Noopur S. Raje, MD Amrita Krishnan, MD, details how she approaches retreating a patient with R/R MM with a BCMA-targeting bispecific agent.
EP. 13: Data Updates on Immunotherapy Combinations in Multiple Myeloma
BySagar Lonial, MD,Amrita Krishnan, MD,Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center,Hana Safah, MD,Noopur S. Raje, MD Krina Patel, MD, reviews recent data from the MAJESTIC studies on immunotherapy combination treatments in R/R MM.
EP. 14: Targets in Multiple Myeloma: GPRC5D
BySagar Lonial, MD,Amrita Krishnan, MD,Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center,Hana Safah, MD,Noopur S. Raje, MD Amrita Krishnan, MD, discusses targeting GPRC5D in multiple myeloma, and where it fits in the treatment sequence.
EP. 15: Targets in Multiple Myeloma: FcRH5
BySagar Lonial, MD,Amrita Krishnan, MD,Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center,Hana Safah, MD,Noopur S. Raje, MD Dr Hana Safah continues the discussion on novel targets in multiple myeloma with a look at FcRH5 and data on cevostamab.
EP. 16: Managing Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity Syndrome in Multiple Myeloma
BySagar Lonial, MD,Amrita Krishnan, MD,Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center,Hana Safah, MD,Noopur S. Raje, MD Noopur Raje, MD, muses on how to manage CRS and ICANS in patients being treated for multiple myeloma, and how serious these conditions truly are.
EP. 17: Preventing Infection in Patients with Multiple Myeloma During Treatment
BySagar Lonial, MD,Amrita Krishnan, MD,Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center,Hana Safah, MD,Noopur S. Raje, MD Sagar Lonial, MD, starts a conversation on infection and hypogamma prevention in patients receiving CAR-T therapy for multiple myeloma.
EP. 18: Does Belantamab Have a Place in Multiple Myeloma Treatment?
BySagar Lonial, MD,Amrita Krishnan, MD,Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center,Hana Safah, MD,Noopur S. Raje, MD The panel takes a look at the possible re-approval of belantamab as a treatment for multiple myeloma in the future.
EP. 19: Unmet Needs and Future Perspectives in Multiple Myeloma Care
BySagar Lonial, MD,Amrita Krishnan, MD,Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center,Hana Safah, MD,Noopur S. Raje, MD The panel closes their discussion with a look at the remaining unmet needs in multiple myeloma treatment.
